Mobile

A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, UK427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudine ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001914-15

A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, UK427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudine for the treatment of antiretroviral-naïve HIV-1 infected subjects

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess whether the antiviral activity (ie, fewer than 400/50 HIV-1 RNA copies per mL of plasma at week 48), of each of the 2 doses of UK-427,857 in combination with ziduvudine/lamivudine is non-inferior to a reference regimen of efavirenz plus zidovudine in antiretroviral-naïve, CCR5-tropic HIV-1 infected subjects.

Critère d'inclusion

  • UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive

Liens